Åsa Wallin
51 – 56 of 56
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2006
-
Mark
CSF Biomarkers for Alzheimer's Disease: Levels of beta-Amyloid, Tau, Phosphorylated Tau Relate to Clinical Symptoms and Survival.
(
- Contribution to journal › Article
-
Mark
Two-year outcome of Galantamine treatment in Alzheimer’s disease in a routine clinical setting.
2006) 9th International Geneva/Springfield Symposium on Advances in Alzheimer Therapy(
- Contribution to conference › Poster
-
Mark
New regression models for long-term cognitive change in Donepezil treated Alzheimer patients.
2006) 9th International Geneva/Springfield Symposium on Advances in Alzheimer Therapy(
- Contribution to conference › Poster
-
Mark
2-års resultat av rivastigmin (Exelon®) behandling vid Alzheimers sjukdom i klinisk vardag.
2006) Läkarstämman 2006(
- Contribution to conference › Poster
- 2005
-
Mark
Analysis of the heterogeneity in treatment response to Donepezil in Alzheimer’s disease conclusions from the Swedish Alzheimer Treatment Study Group.
(
- Contribution to conference › Poster
- 2004
-
Mark
Five-Year Outcome of Cholinergic Treatment of Alzheimer's Disease: Early Response Predicts Prolonged Time until Nursing Home Placement, but Does Not Alter Life Expectancy.
(
- Contribution to journal › Article